Drug Trial Radar · NCT06180889
Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
Last checked: Nov 19, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
241
Actual
Start
Dec 20, 2023
Primary completion
Dec 15, 2025
Study completion Apr 15, 2026
Sponsor
- Lead sponsor
- Suzhou Alphamab Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was to compare the study drug KN060 to enoxaparin, for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).
Conditions
- Knee Arthroplasty, Total
Interventions
EnoxaparinDrug
40 mg enoxaparin administered as subcutaneous injection once daily
KN060 LowDrug
Single dose of KN060 administered as intravenous infusion
KN060 MiddleDrug
Single dose of KN060 administered as intravenous infusion
KN060 HightDrug
Single dose of KN060 administered as intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of composite endpoint consisting of asymptomatic DVT as detected by mandatory bilateral venography, objectively confirmed symptomatic DVT, non-fatal PE, fatal PE, unexplained death for which PE cannot be excludedTime frame: Up to 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Sixth People's Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.